CREATING NEXT GENERATION RNA BASED TECHNOLOGY
Advancing Next-Generation RNA based technologies
Veterna is redefining RNA-based medicine with its proprietary trans-amplifying RNA replicon platform, enabling vaccines and potent therapeutics at low doses. This technology drives sustained protein expression from minimal RNA, reducing formulation needs while boosting impact.
Our technology
Our proprietary technology is based on an innovative trans-amplifying RNA (taRNA) platform that enables RNA to self-amplify within the patient’s own cells. Our approach separates the replicase machinery from the payload RNA. Once inside the cell, the replicase amplifies the payload, resulting in high and sustained antigen expression from minimal RNA input. This technology unlocks highly potent RNA vaccines at lower doses—enhancing efficacy while reducing safety risks.
Our Technology
Our technology is based on an innovative trans-amplifying RNA (taRNA) platform that enables RNA to self-amplify within the patient’s own cells. Our approach separates the replicase machinery from the therapeutic payload. Once the taRNA is inside the cell, the replicase amplifies the payload RNA, driving high and sustained antigen expression from minimal RNA input. Using this proprietary split-replicon design, we unlock potent RNA therapies at lower doses—reducing safety risks while maximizing efficacy.
OUR LEADERSHIP TEAM
EXPERIENCED LEADERSHIP
Konrad Stadler
CEO and CSO
Konrad is a co‑founder, CEO and CSO at Veterna, where he serves as the scientific architect of a next‑generation trans‑amplifying RNA vaccine platform for infectious diseases...
drawing on more than 25 years of experience in preclinical and translational vaccine development across industry, academia and public–private partnerships.
Previously, he was CSO at Viroclinics-DDL and led the vaccine program at the German Center for Infectious Disease Research. He has held senior roles including Global Head of R&D for Swine Vaccines at Ceva Santé Animale, General Manager of the Ceva Innovation Center in Dessau, Germany, and Head of Animal Vaccine R&D, EU at Boehringer Ingelheim. Additionally, he was Head of Molecular Microbiology at the International Vaccine Institute in Seoul, South Korea, and previously worked as a senior scientist at Chiron Vaccines and Novartis Vaccines in Siena, Italy. Konrad holds a doctoral degree in biochemistry from the University of Vienna, Austria
Melanie Sno
Project Manager
Melanie is a project manager at Veterna...
Prior to that she was a global senior project manager at Ceva Santé Animale, located in Hungary, developing new veterinary vaccines as well as supporting existing products on a global level with collaborations and/or projects in Europe, the US and Asia. Her career started at MSD Animal Health in the Netherlands where, over a period of 15 years, she worked first as a scientist, before becoming a project leader for swine vaccine development projects after completion of her masters.
Randolph Seidler
Consultant
Randolph is a co-founder and consultant and has extensive R&D and portfolio leadership experience...
As Head of Global R&D and Regulatory Affairs for 10 years at Boehringer Ingelheim Animal Health (BIAH), he oversaw the global research, development and registration of multiple highly innovative drugs and vaccines. During this time BIAH brought multiple new molecular entities (vaccines and pharmaceuticals) to all major markets.
During his career he also held the position of Global Head of Business Development, Licensing and Alliance Management, where he oversaw the successful negotiation of several joint ventures, technology licenses and equity investments. Prior to this he held various international positions of growing responsibility within Boehringer Ingelheim’s human pharma R&D organization, including roles in cardiovascular diseases in the US and in Germany.
In addition to his role in Veterna, Randolph supports several animal health startup companies through supervisory and advisory board positions. Randolph holds a degree in Veterinary Medicine and a Doctorate in physiology from the Ludwig-Maximilians-University in Munich, Germany and an Executive MBA from INSEAD in Fontainebleau, France.
Gianclaudio Antonelli
Gianclaudio is a co-founder of Veterna and is currently serving as consultant regarding administration, finance and legal...
In this function he had a key role in securing the research funding from R3 Wellcome Leap. He is also serving as managing director of our Italian affiliate company Veterna srl. Prior to Vaxeleron, he served as CFO for the Italian start-up Contraria Biotech (formerly Achilles Vaccines) where he was instrumental in the negotiation and implementation its first two rounds of seed financing which, at the time, was the largest ever in Italy.
Before entering the biotechnology arena, Gianclaudio spent almost 25 years in the finance industry covering operative and management roles in both sell-side and buy-side front office, risk management and compliance.
He was Head of Alternative Investments for the C-Quadrat Investment group as well as COO of their UK subsidiary. Gianclaudio holds a degree in Management of Financial Institutions from the Università Bocconi in Milan, Italy; he holds CFA and CIMA Dip MA qualifications.
SCIENTIFIC ADVISORY BOARD
Sir Michael Houghton
Nobel Laureate Sir Michael Houghton is the Li Ka Shing Professor of Virology at the University of Alberta and Director of the Li Ka Shing Applied Virology Institute. He was jointly awarded the 2020 Nobel Prize in Physiology or Medicine, together with Harvey J. Alter and Charles M. Rice, for the discovery of hepatitis C virus (HCV), and was knighted by Queen Elizabeth II in 2020 for services to medicine.
Born in the United Kingdom, Dr. Houghton obtained a BSc in biological sciences from the University of East Anglia and a PhD in biochemistry from King’s College London. He began his career at G.D. Searle & Company in the UK before joining Chiron Corporation in California, where, together with colleagues Qui-Lim Choo and George Kuo, and Daniel W. Bradley from the U.S. Centers for Disease Control and Prevention, he first identified HCV in 1989. He authored seminal studies that led to the blood screening tests introduced in the early 1990s, which eliminated hepatitis C contamination from donated blood supplies worldwide, and identified key viral replication enzymes that became critical targets for today’s highly effective antiviral therapies.
Albert Osterhaus
Professor Ab Osterhaus served as Head of the Department of Viroscience at Erasmus MC in Rotterdam until 2014 and is currently Director of the Center of Infection Medicine and Zoonosis Research and Guest Professor at the University of Veterinary Medicine, Hannover. He has an extensive track record as a scientific researcher and Principal Investigator of numerous major projects, pioneering an integrated “viroscience” approach bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies on human and animal virus infections.
Professor Osterhaus has discovered multiple new human and animal viruses, including the human metapneumovirus, influenza and coronaviruses, and has elucidated the pathogenesis of major viral infections while developing novel intervention strategies. This work has enabled health authorities such as the WHO to more effectively combat outbreaks including SARS and avian influenza. He has supervised over 80 PhD students, holds several key patents, and has authored more than 1,300 peer-reviewed publications. His international standing is reflected in major scientific awards, invited lectureships, membership in the Dutch and German National Academies of Sciences, and the Belgian Academy of Medicine, and his appointment as Commander of the Order of the Dutch Lion.
Alan Liss
Dr. Alan Liss has over 35 years of experience in the areas of vaccines, plasma products, and biologics product development and manufacturing. Alan has held a variety of industry and academic appointments, authored over 60 scientific publications. He received a Bachelor of Science degree in Genetics from the University of California, Berkeley in 1969, and his Ph.D. in Microbiology and Immunology from the University of Rochester, School of Medicine and Dentistry in 1974. Alan retired from FDA where he directed the Public Health and Security Action Team Program within the Office of the Commissioner. Alan has lectured globally in the areas of using effective quality and compliance programs needed to enhance product development and manufacturing and on the fundamental principles needed for effective engagement with FDA throughout the product development process. Alan and the GXP farma team currently focus on the growing vaccine and biopharma industries located outside of the continental USA.